ReviewCurrent opinion in pharmacology2006
Angiotensin-converting enzyme 2 in lung diseases.
Review in Current opinion in pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 246 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
246 citing papers in PubMed, 5 syntheses or guidelines pooled it, 409 citations in OpenAlex.
- Bone Mineral Density, Bone Biomarkers, and Joints in Acute, Post, and Long COVID-19: A Systematic Review.Viruses · 2024Pooled it
- Relationship between Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and the Risk of COVID-19: A Meta-Analysis.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2023Pooled it
- Pooled it
- Cumulative Evidence for the Association of Thrombosis and the Prognosis of COVID-19: Systematic Review and Meta-Analysis.Frontiers in cardiovascular medicine · 2021Pooled it
- Pooled it
- The protective effect of chemical and natural compounds against amiodarone induced toxicity: A systematic review.Biochemistry and biophysics reports · 2026Review
- Tenofovir attenuates cytokine storm and bronchiolar damage in a mouse model of bleomycin-induced acute lung injury.Scientific reports · 2025Article
- Associations of metabolic syndrome with lung function decline and clinical respiratory outcomes: the NHLBI Pooled Cohort Study.ERJ open research · 2025Article
- Hemodynamic Definitions, Phenotypes, Pathophysiology, and Evaluation of Pulmonary Hypertension Related to Left Heart Disease.Journal of cardiovascular development and disease · 2025Review
- Increased antioxidative defense and reduced advanced glycation end-product formation by metabolic adaptation in non-small-cell-lung-cancer patients.Nature communications · 2025Article
- Association of TLR8 Variants in Sex-Based Clinical Differences in Patients with COVID-19.Biochemical genetics · 2025Article
- Evaluation of Anti-SARS-CoV-2 IgG Responses in a Clinical Study of a Biosimilar Candidate to Denosumab Using Singlicate Analysis.Drugs in R&D · 2025Article
- COVID-19 and ACE2 Receptor in Different Tissues: From Pathophysiologic Function To Therapeutic Responses.Archives of Razi Institute · 2025Review
- Gating Mechanism for Biased Agonism at Angiotensin II Type 1 Receptors.Molecules (Basel, Switzerland) · 2025Article
- Bridging Cancer and COVID-19: The Complex Interplay of ACE2 and TMPRSS2.Cancer medicine · 2025Review
- Article
- Mediterranean Diet as a Therapeutic Strategy for Hypertension and Cardiovascular Health.International journal of hypertension · 2025Review
- Case Report: Successful weaning after 113 days of VV-ECMO in a pediatric patient with severe ARDS following Stevens-Johnson syndrome.Frontiers in pediatrics · 2025Article
- Incidence and Outcomes of Vertebral Compression Fracture Among Patients Infected with COVID-19.Journal of clinical medicine · 2024Article
- Vascular fibrosis and extracellular matrix remodelling in post-COVID 19 conditions.Infectious medicine · 2024Review
186 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The renin-angiotensin system (RAS) plays a key role in maintaining blood pressure homeostasis, as well as fluid and salt balance. Angiotensin II, a key effector peptide of the system, causes vasoconstriction and exerts multiple biological functions. Angiotensin-converting enzyme (ACE) plays a central role in generating angiotensin II from angiotensin I, and capillary blood vessels in the lung are one of the major sites of ACE expression and angiotensin II production in the human body. The RAS has been implicated in the pathogenesis of pulmonary hypertension and pulmonary fibrosis, both commonly seen in chronic lung diseases such as chronic obstructive lung disease. Recent studies indicate that the RAS also plays a critical role in acute lung diseases, especially acute respiratory distress syndrome (ARDS). ACE2, a close homologue of ACE, functions as a negative regulator of the angiotensin system and was identified as a key receptor for SARS (severe acute respiratory syndrome) coronavirus infections. In the lung, ACE2 protects against acute lung injury in several animal models of ARDS. Thus, the RAS appears to play a critical role in the pathogenesis of acute lung injury. Indeed, increasing ACE2 activity might be a novel approach for the treatment of acute lung failure in several diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.